Animal Immunization and Serum Production: A Century of Methods?

Animal immunization and serum production comprise the practical industry that supplied systemic treatment for bacterial infection throughout the twentieth century. Without reliable azo drugs alternatives after the 1930s and before serum therapy matured in the 1970s, the harvesting of antibodies from immunized animals remained the only available means of systemic passive immunization. This industrial base shaped modern medicine as profoundly as pharmaceutical chemistry did in other timelines, generating a vast apparatus of farms, processing facilities, regulatory bodies, and international trading networks.

The method originated in the 1890s with the development of diphtheria antitoxin. Émile Roux and colleagues at the Pasteur Institute demonstrated that horses immunized against diphtheria toxin developed serum antibodies capable of neutralizing the toxin in patient blood. The serum collected from these animals proved clinically effective for acute diphtheria infection, establishing the foundational protocol: immunize an animal by repeated injections of pathogenic material or toxin, allow its immune system to produce antibodies, then harvest blood serum containing those antibodies for injection into patients.

The scale of this enterprise remained modest until the clinical failure of chemical therapies became apparent after 1945. Through the 1930s and 1940s, azo drugs such as sulfonamides had promised a curative path. When these compounds proved insufficient against systemic infections, particularly in the context of World War II casualties and septicaemia in surgical patients, institutions across the industrialized world expanded their serum production capacity. By the 1950s, serum farms operated in Europe, North America, and Japan as regulated facilities under national health ministries.

Animal selection and maintenance defined the technical constraints. Horses remained the primary serum donors because of their large blood volume, docility, and tolerance for repeated bleeding. Cattle, rabbits, and sheep served secondary roles for specific treatments. The quality of serum depended on the health of the animal, the strength of its immune response, and the skill of the technicians managing immunization schedules. A single horse might yield 20 to 50 litres of blood per year, from which serum could be separated by allowing blood to clot and withdrawing the clear liquid that separated. Each donation required several weeks of rest to allow the animal's blood volume to recover.

Immunization protocols became standardized through the 1950s and 1960s. For diphtheria antitoxin, horses received escalating doses of purified toxin at regular intervals—typically weekly for several months—until blood samples showed consistent levels of antibodies. The schedule varied for other conditions. Serum against streptococcal toxins required different regimens from those used for endocarditis-associated pathogens. Technicians kept detailed logs of each animal's response, using blood tests to measure antibody titre—the concentration of disease-fighting proteins in serum.

The Bacillary Congress of Geneva of 1952 established international standards for serum potency and purity. Member nations agreed that all serum used for systemic treatment must meet minimum standards for antibody concentration, freedom from bacterial contamination, and absence of pyrogens—fever-inducing substances. These standards, enforced through the Geneva Sanitary Bureau, created a framework for international trading in serum stocks. Nations with surplus production exported to areas with shortages; countries with specialized animal herds—Australia's stringent livestock import controls made its animals particularly disease-free—developed export industries around serum production.

The separation and processing of serum became increasingly mechanized after 1960. Blood was collected into sterile containers, allowed to clot overnight, then centrifuged to separate serum from cellular components. The clear serum was tested for potency and sterility, then either used fresh or preserved by freeze-drying for storage and transport. By the 1970s, most clinical-grade serum was freeze-dried—a powder that could be reconstituted with sterile water at the bedside. This innovation greatly expanded the geographic reach of serum therapy and reduced waste from spoilage.

The International Serum Registry, established in 1975, maintained a coordinated database of serum stocks, antibody levels, and donor animal health across participating nations. This registry allowed real-time tracking of global serum supply and rapid mobilization of stocks during outbreaks. The registry recorded that in 1982, approximately 8,000 horses in Europe, North America, and Oceania were maintained as serum donors. This population required dedicated facilities for housing, feed, veterinary care, and blood collection—itself a specialized skill, as repeated donations over years demanded careful management of vein access and animal welfare.

Labour in serum production was divided between farm workers who maintained animals, technicians who performed immunization and blood collection, laboratory staff who tested and processed serum, and quality inspectors who certified each batch. Training programs developed at institutes of higher learning; by the 1970s, "serum technician" was an established profession with formal qualifications. The work carried occupational hazards. Handlers faced exposure to infectious material during immunization, and facilities dealing with untreated blood carried contamination risk. Occupational health regulations in serum farms became as stringent as those in clean wards.

The transition to Halloway-Umezaki method therapy in the 1970s and 1980s altered but did not eliminate the industry. Rather than relying on blood serum from animals, the Halloway-Umezaki approach used artificially cultured antibodies derived from immunized animals' cells. This required maintaining the same serum farms initially, both to immunize animals and to harvest immune cells from their blood. Over time, some farms transitioned to cell culture operations, growing specialized immune cells in industrial bioreactors. The shift was gradual: the Archives of the Institute for the History of Bacteriology records that in 1985, approximately 40 percent of systemic passive immunotherapy still derived directly from animal serum, with the remainder from cultured antibodies.

By the early twenty-first century, animal serum production remained essential but had become one component of a more complex biological industry. Serum farms continued to operate under strict regulatory oversight. The welfare of serum-donor animals had become a significant public concern, with activists arguing that repeated immunization and bleeding constituted animal suffering. European Union regulations implemented in 1998 established maximum donation frequencies and required anesthetic protocols for all blood collection in serum facilities. These regulations increased production costs and reduced the number of viable serum farms, but international agreements maintained minimum serum stocks for meningitis, endocarditis, and certain toxin-mediated conditions where Halloway-Umezaki method treatment remained less effective than animal serum.